Iteos Therapeutics Inc.

10/24/2024 | Press release | Distributed by Public on 10/24/2024 05:14

iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A 005 Clinical Trial Data in 2L NSCLC at ESMO Immuno Oncology Congress